 |
| Gator's Chart of the Day: ROSG |
There was news on May 16th that Novitas will be using ROSG's miRview mets2 assay for all Medicare beneficiaries and that could be what has been driving the stock. After market today there was more news and it may very well drive the stock lower.
"PHILADELPHIA, PA and REHOVOT, ISRAEL--(Marketwire -05/24/12)- Rosetta Genomics Ltd. ("Rosetta") (ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced it has entered into definitive agreements with investors to purchase an aggregate of 570,755 ordinary shares at a price of $11.50 per share in a registered direct offering. The offering is expected to close on or about May 31, 2012, subject to the satisfaction of customary closing conditions."
If you want to grab this tiger's tail be careful. The moves have been fast and furious.